Home › Endometrial Cancer › New Mexico
Endometrial Cancer clinical trials in New Mexico
13 studies for Endometrial Cancer are looking for participants at sites in New Mexico.
Cities in New Mexico
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- University of New Mexico Cancer Center, Albuquerque
RecruitingPhase 2
All ages · All sexes · Updated Oct 2, 2026 · NCT05564377Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
- University of New Mexico Cancer Center, Albuquerque
RecruitingPhase 1
Ages 18 and older · Women · Updated Oct 2, 2026 · NCT05950464Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- University of New Mexico Cancer Center, Albuquerque
RecruitingPhase 3
Ages 18 and older · Women · Updated Oct 2, 2026 · NCT07198074Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- University of New Mexico Cancer Center, Albuquerque
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 28, 2026 · NCT05112601DESTINY-PANTUMOUR04
- Research Site, Farmington
RecruitingObservational study
Ages 18 to 130 · All sexes · Updated Sep 25, 2026 · NCT07124000Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Albuquerque
RecruitingPhase 2
Ages 18 to 130 · All sexes · Updated Sep 23, 2026 · NCT05489211A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- University of New Mexico Comprehensive Cancer Center ( Site 6046), Albuquerque
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 17, 2026 · NCT06952504A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Albuquerque
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT05123482Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- Research Site, Albuquerque
RecruitingPhase 3
Ages 18 and older · Women · Updated Jul 29, 2026 · NCT07044336Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
- 292, Albuquerque
RecruitingPhase 2
Ages 18 and older · Women · Updated Jul 16, 2026 · NCT06906341Uterine Preservation Via Lifestyle Transformation
- University of New Mexico, Albuquerque
RecruitingPhase 2
Ages 18 and older · Women · Updated Jan 20, 2026 · NCT05903131Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
- University of New Mexico, Albuquerque
RecruitingPhase 1
Ages 18 and older · Women · Updated Dec 11, 2025 · NCT06795009SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Albuquerque
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.